Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS EBITDA Margin

EBITDA as a percentage of revenue.

Viatris Inc.NASDAQ: VTRS

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 19.4%

EBITDA Margin was 19.4% in Q2 FY2026, up 3.3 pp from a year earlier. On a trailing-twelve-month basis it was 18.4%, up 21.9 pp year over year. Over 3 fiscal years it narrowed by 42.3 pp.

Context

  • EBITDA Margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 45.0% for the fiscal year ending Dec 2026, up from -2.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
19.4%+1.1 pp QoQ
Last fiscal yearDec 2025
-2.8%-20.6 pp YoY
LTMJun 2026
18.4%+21.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.3 pp+24.4 pp+21.2 pp
1 year-20.6 pp+47.8 pp+68.4 pp
3 years-42.3 pp+43.0 pp+85.3 pp
5 years+40.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2.8%
Year-over-year change
-20.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How VTRS compares with its peers on the latest reported figures

  • VTRS's LTM Jun 2026 EBITDA Margin of 18.4% is the 7th highest of the 10 companies compared; the peer median is 20.9%.
  • Its year-over-year change of +21.9 pp is the highest of 9, against a peer median of -6.3 pp.
  • Over three fiscal years its change of -42.3 pp compares with a peer median of +0.2 pp.
VTRS Competitors Peer median
EBITDA Margin for VTRS and competitors
Company Period LTM level YoY 3-year change
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202626.6% -9.0 pp+0.2 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202625.4% +15.5 pp+15.5 pp
HLNHaleon plcLTM Jun 202524.4% —+6.0 pp
OGNOrganon & Co.LTM Sep 202621.2% -3.6 pp-7.7 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202620.9% +0.5 pp+0.1 pp
BHCBausch Health Companies Inc.LTM Jun 202618.9% -14.3 pp-4.5 pp
VTRSViatris Inc.LTM Jun 202618.4% +21.9 pp-42.3 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202616.3% -12.5 pp-6.7 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202615.0% -2.9 pp+24.4 pp
ALKSAlkermes plcLTM Sep 202610.2% -18.5 pp+17.0 pp
Peer median (excluding VTRS) 20.9%-6.3 pp+0.2 pp

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.89B16.26B15.43B14.74B14.3B
Cost of Revenue12.31B9.77B8.99B9.12B9.29B
Gross Profit5.58B6.5B6.44B5.62B5.01B
Gross Margin31.2%40.0%41.7%38.2%35.1%
Research & Development681M662.2M805.2M808.7M965.9M
Selling, General & Admin4.53B4.18B4.65B4.43B3.79B
Operating Expenses5.61B4.88B5.67B5.61B7.68B
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
EBITDA4.48B6.43B3.52B2.64B(395.4M)
EBITDA Margin25.0%39.6%22.8%17.9%-2.8%
Operating Income(34M)1.61B766.2M10.1M(2.66B)
Operating Margin-0.2%9.9%5.0%0.1%-18.6%
Interest Income00000
Interest Expense636.2M592.4M573.1M550M471.3M
Other Income / Expenses(630.4M)1.2B(563.3M)(633.3M)(1B)
Income Before Tax(664.4M)2.81B202.9M(623.2M)(3.67B)
Pre-Tax Margin-3.7%17.3%1.3%-4.2%-25.6%
Income Tax Expense604.7M734.6M148.2M11M(150.1M)
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Net Margin-7.1%12.8%0.4%-4.3%-24.6%
EPS (Basic)(1.05)1.710.05(0.53)(3.00)
EPS (Diluted)(1.05)1.710.05(0.53)(3.00)
Weighted Avg Shares1.21B1.21B1.2B1.19B1.17B
Weighted Avg Shares (Diluted)1.21B1.22B1.21B1.19B1.17B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.